Deferasirox exerts anti-epileptic effects by improving brain iron homeostasis via regulation of ITPRIP.
Neurochem Int
; 176: 105725, 2024 Jun.
Article
em En
| MEDLINE
| ID: mdl-38561151
ABSTRACT
Epilepsy constitutes a global health concern, affecting millions of individuals and approximately one-third of patients exhibit drug resistance. Recent investigations have revealed alterations in cerebral iron content in both epilepsy patients and animal models. However, the extant literature lacks a comprehensive exploration into the ramifications of modulating iron homeostasis as an intervention in epilepsy. This study investigated the impact of deferasirox, a iron ion chelator, on epilepsy. This study unequivocally substantiated the antiepileptic efficacy of deferasirox in a kainic acid-induced epilepsy model. Furthermore, deferasirox administration mitigated seizure susceptibility in a pentylenetetrazol-induced kindling model. Conversely, the augmentation of iron levels through supplementation has emerged as a potential exacerbating factor in the precipitating onset of epilepsy. Intriguingly, our investigation revealed a hitherto unreported discovery ITPRIP was identified as a pivotal modulator of excitatory synaptic transmission, regulating seizures in response to deferasirox treatment. In summary, our findings indicate that deferasirox exerts its antiepileptic effects through the precise targeting of ITPRIP and amelioration of cerebral iron homeostasis, suggesting that deferasirox is a promising and novel therapeutic avenue for interventions in epilepsy.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Encéfalo
/
Quelantes de Ferro
/
Epilepsia
/
Deferasirox
/
Ferro
/
Proteínas de Membrana
/
Anticonvulsivantes
Limite:
Animals
Idioma:
En
Revista:
Neurochem Int
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
China